“During the year (FY23), the customer decision-making got delayed due to macro-economic environment and pipeline prioritisation based on limited capital availability, especially for the emerging biotech companies which impacted our order inflows and hence our revenue growth,” said Nandini Piramal, chairperson, Piramal Pharma, at company’s annual general meeting (AGM) on Monday.
